Clinical and functional remission: Even though biologics are superior to conventional DMARDs overall success rates remain low - Results from RABBIT, the German biologics register

Arthritis Research and Therapy

Volumn 8, Issue 3, 2006, Pages

  Listing, Joachim ^a   Strangfeld, Anja ^a   Rau, Rolf ^b   Kekow, Jörn ^c   Gromnica Ihle, Erika ^d   Klopsch, Thilo ^e   Demary, Winfried ^e   Burmester, Gerd Rüdiger ^f   Zink, Angela ^a,f  

^a German Rheumatism Research Centre   (Germany)

^b Evangelisches Fach krankenhaus Ratingen   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d Rheumaklinik Berlin Buch   (Germany)

^e Charité University Hospital ^*  (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT;

ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; COHORT ANALYSIS; COMPARATIVE STUDY; GERMANY; HUMAN; MIDDLE AGED; REGISTER; TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COHORT STUDIES; GERMANY; HUMANS; MIDDLE AGED; REGISTRIES; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 70350554084     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar1933     Document Type: Article

References (33)

1. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939.
2. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, et al.: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999, 130:478-486.
3. van de Putte BA, Atkins C, Malaise M, Sany J, Russell AS, van Riel PLCM, Settas L, Biljsma JW, Todesco S, Dougados M, et al.: Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004, 63:508-516.
4. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin- 1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double- blind, placebo-controlled trial. Arthritis Rheum 2002, 46:614-624.
5. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003, 48:35-45.
6. Sokka T, Pincus T: Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003, 48:313-318.
7. Pincus T, Sokka T, Kavanaugh A: Relative versus absolute goals of therapies for RA: ACR 20 or ACR 50 responses versus target values for linear remission" of DAS or single measures. Clin Exp Rheumatol 2004, 22:S50-S56.
8. Fransen J, Creemers MCW, van Riel PLCM: Remission in rheumatoid arthritis: Agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria.Rheumatology 2004, 43 1252-1255.
9. Pinals RS, Masi AT, Larsen RA: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981, 24 1308-1315.
10. Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, von Hinueber U, Gromnica-Ihle E, Wassenberg S, Antoni C, et al.: Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005, 64 1274-1279.
11. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova- Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, et al.: Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005, 52:3403-3412.
12. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
13. Westhoff G, Listing J, Zink A: Loss of physical independence in rheumatoid arthritis: Interview data from a representative sample of patients treated in tertiary rheumatologic care. Arthritis Care Res 2000, 13:11-21.
14. Lautenschlaeger J, Mau W, Kohlmann T, Raspe HH, Struve F, Bruckle W, Zeidler H: Comparative evaluation of a German version of the Health Assessment Questionnaire (HAQ) and the Hanover Functional Status Questionnaire (HFSQ) [Vergleichende Evaluation einer deutschen Version des Health Assessment Questionnaires (HAQ) und des Funktionsfragebogens Hannover (FFbH).]. Z Rheumatol 1997:144-155.
15. Fries JF: The Assessment of Disability - from 1St to Future Principles. Br J Rheumatol 1983, 22:48-58.
16. Mäkinen H, Kautiainen H, Hannonen P, Sokka T: Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005, 64:1410-1413.
17. Zink A, Listing J, Klindworth C, Zeidler H, for the German Collaborative Arthritis Centres: The National Database of the German Collaborative Arthritis Centres. Structure, aims, and patients. Ann Rheum Dis 2001, 60:199-206.
18. Steinbrocker O, Traeger CH, Battermann RC: Therapeutic criteria in rheumatoid arthritis. JAMA 1949, 140:659-662.
19. Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika 1983, 70:41-55.
20. van der Heijde D, Klareskog L, Boers M, Landewe R, Codreanu C, Bolosiu HD, Pedersen R, Fatenejad S: Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 2005, 64:1582-1587.
21. Harrison BJ, Symmons DPM, Brennan P, Barrett EM, Silman AJ: Natural remission in inflammatory polyarthritis: Issues of definition and prediction. Br J Rheumatol 1996, 35:1096-1100.
22. Paulus HE: Defining remission in rheumatoid arthritis: What is it? Does it matter? J Rheum 2004, 31:1-4.
23. Balsa A, Carmona L, Gonzalez-Alvaro I, Belmonte MA, Tena X, Sanmarti R: Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American college of Rheumatology defined remission in rheumatoid arthritis. J Rheum 2004, 31:40-46.
24. Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS: Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states. Arthritis Rheum 2005, 52 2625-2636.
25. Verstappen SMM, Albada-Kuipers GAV, Bijlsma JWJ, Blaauw AAM, Schenk Y, Haanen HCM, Jacobs JWG: A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis 2005, 64:38-43.
26. Krishnan E, Hakkinen A, Sokka T, Hannonen P: Impact of age and comorbidities on the criteria for remission and response in rheumatoid arthritis. Ann Rheum Dis 2005, 64:1350-1352.
27. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum 2004, 50 3432-3443.
28. Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Hakala M, Jarvinen P, Ahonen J, Forsberg S, Leirisalo-Repo M: Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheuma toid arthritis - Five-year experience from the FIN-RACo trial. Arthritis Rheum 2005, 52:36-41.
29. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet 2004, 364:263-269.
30. Pincus T, Sokka T, Kautiainen H: Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum 2005, 52:1009-1019.
31. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Mola EM, Pavelka K, Sany J, Settas L, et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 2004, 363:675-681.
32. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ: A trial of etanercept, a recombinant tumor necrosis factor receptor:FC fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253-259.
33. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343 1594-1602.